{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:15:28Z","timestamp":1786979728970,"version":"build-2736575974"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T00:00:00Z","timestamp":1654473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T00:00:00Z","timestamp":1654473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urogynecol J"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s00192-022-05250-1","type":"journal-article","created":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T09:04:02Z","timestamp":1654506242000},"page":"2127-2132","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["On-demand use of fesoterodine: a new paradigm for extended release antimuscarinics"],"prefix":"10.1007","volume":"33","author":[{"given":"Ibrahim Halil","family":"Bozkurt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ertugrul","family":"Sefik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serdar","family":"Celik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arda","family":"Yesilova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Koras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tansu","family":"Degirmenci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,6]]},"reference":[{"key":"5250_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/nau.20798","volume":"29","author":"BT Haylen","year":"2010","unstructured":"Haylen BT, et al. An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29:4.","journal-title":"Neurourol Urodyn"},{"key":"5250_CR2","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1097\/AOG.0000000000000468","volume":"124","author":"M Kalder","year":"2014","unstructured":"Kalder M, Pantazis K, Dinas K, et al. Discontinuation of treatment using anticholinergic medications in patients with urinary incontinence. Obstet Gynecol. 2014;124:794\u2013800. https:\/\/doi.org\/10.1097\/AOG.0000000000000468.","journal-title":"Obstet Gynecol"},{"key":"5250_CR3","doi-asserted-by":"crossref","unstructured":"Shamliyan T, Wyman J, Kane RL. Nonsurgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Apr. Report No.: 11(12)-EHC074-EF.","DOI":"10.7326\/0003-4819-156-12-201206190-00436"},{"key":"5250_CR4","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.eururo.2008.06.080","volume":"54","author":"G Novara","year":"2008","unstructured":"Novara G, et al. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol. 2008;54:740.","journal-title":"Eur Urol"},{"key":"5250_CR5","unstructured":"EAU. Guidelines on non-neurogenic female LUTS. 2021. Accessed at 07\/03\/2022."},{"key":"5250_CR6","first-page":"273","volume":"13","author":"C G\u00fcngen","year":"2002","unstructured":"G\u00fcngen C, Ertan C, Eker E, et al. Standardize mini mental test\u2019 in T\u00fcrk toplumunda hafif demans tan\u0131s\u0131nda ge\u00e7erlik ve g\u00fcvenilirli\u011fi. T\u00fcrk Psikiyatri Dergisi. 2002;13:273\u201381.","journal-title":"T\u00fcrk Psikiyatri Dergisi"},{"key":"5250_CR7","first-page":"332","volume":"30","author":"B Cetinel","year":"2004","unstructured":"Cetinel B, Ozkan B, Can G. ICIQ-SF T\u00fcrk\u00e7e versiyonu validasyon (ge\u00e7erlilik) \u00e7al\u0131\u015fmas\u0131. T\u00fcrk \u00dcroloji Dergisi. 2004;30:332\u20138.","journal-title":"T\u00fcrk \u00dcroloji Dergisi"},{"key":"5250_CR8","volume-title":"\"SEAPI QMM sorgulama formununT\u00fcrk\u00e7e validasyonu ve TVT ba\u015far\u0131s\u0131 de\u011ferlendirmesinde kullan\u0131lmas\u0131,\" 1","author":"T Tarcan","year":"2007","unstructured":"Tarcan T, Akbal C, Tinay I, et al. \"SEAPI QMM sorgulama formununT\u00fcrk\u00e7e validasyonu ve TVT ba\u015far\u0131s\u0131 de\u011ferlendirmesinde kullan\u0131lmas\u0131,\" 1. Antalya: Pelvik Taban Sa\u011fl\u0131\u011f\u0131 ve \u0130\u015feme Bozukluklar\u0131 Kongresi; 2007."},{"key":"5250_CR9","first-page":"113","volume":"21","author":"T Tarcan","year":"2012","unstructured":"Tarcan T, Mangir N, Ozgur MO, et al. OAB V-8 A\u015f\u0131r\u0131 aktif mesane sorgulama formu validasyon \u00e7al\u0131\u015fmas\u0131. \u00dcroloji B\u00fclteni. 2012;21:113\u20136.","journal-title":"\u00dcroloji B\u00fclteni"},{"key":"5250_CR10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.12816\/0043080","volume":"70","author":"MF Alla","year":"2018","unstructured":"Alla MF, Mahmoud AM, Sayed Youssef AE. Safety and efficacy of intermittent versus continuous anticholinergic medication in management of overactive bladder in adult. Egyptian J Hospital Med. 2018;70:223\u20137.","journal-title":"Egyptian J Hospital Med"},{"key":"5250_CR11","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1093\/ageing\/afv077","volume":"44","author":"M Oelke","year":"2015","unstructured":"Oelke M, Becher K, Castro-Diaz D, et al. Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014). Age Ageing. 2015;44:745\u201355.","journal-title":"Age Ageing"},{"issue":"2","key":"5250_CR12","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1365-2125.2011.03948.x","volume":"72","author":"B Malhotra","year":"2011","unstructured":"Malhotra B, Darsey E, Crownover P, Fang J, Glue P. Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers. Br J Clin Pharmacol. 2011;72(2):226\u201334. https:\/\/doi.org\/10.1111\/j.1365-2125.2011.03948.x.","journal-title":"Br J Clin Pharmacol"},{"key":"5250_CR13","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/j.1524-4733.2007.00295.x","volume":"11","author":"UB Campbell","year":"2008","unstructured":"Campbell UB, Stang P, Barron R. Survey assessment of continuation of and satisfaction with pharmacological treatment for urinary incontinence. Value Health. 2008;11:726\u201332. https:\/\/doi.org\/10.1111\/j.1524-4733.2007.00295.x.","journal-title":"Value Health"},{"key":"5250_CR14","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1111\/j.1532-5415.2011.03473.x","volume":"59","author":"A Paquette","year":"2011","unstructured":"Paquette A, Gou P, Tannenbaum C. Systematic review and meta-analysis: Do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events? J Am Geriatr Soc. 2011;59:1332\u20139.","journal-title":"J Am Geriatr Soc"},{"issue":"9","key":"5250_CR15","doi-asserted-by":"publisher","first-page":"E378","DOI":"10.5489\/cuaj.5032","volume":"12","author":"M Przydacz","year":"2018","unstructured":"Przydacz M, Campeau L, Walter JE, Corcos J. How long do we have to treat overactive bladder syndrome (OAB)? A questionnaire survey of Canadian urologists and gynecologists. Can Urol Assoc J. 2018;12(9):E378\u201383. https:\/\/doi.org\/10.5489\/cuaj.5032.","journal-title":"Can Urol Assoc J"},{"key":"5250_CR16","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/01.ju.0000161597.30736.21","volume":"174","author":"MS Choo","year":"2005","unstructured":"Choo MS, Song C, Kim JH, et al. Changes in overactive bladder symptoms after discontinuation of successful 3-month treatment with an antimuscarinic agent: a prospective trial. J Urol. 2005;174:201\u20134. https:\/\/doi.org\/10.1097\/01.ju.0000161597.30736.21 Erratum in: J Urol. 2005 Oct;174(4 Pt 1):1505.","journal-title":"J Urol"},{"key":"5250_CR17","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1111\/j.1742-1241.2011.02728.x","volume":"65","author":"YS Lee","year":"2011","unstructured":"Lee YS, Choo MS, Lee JY, et al. Symptom change after discontinuation of successful antimuscarinic treatment in patients with overactive bladder symptoms: a randomised, multicentre trial. Int J Clin Pract. 2011;65:997\u20131004. https:\/\/doi.org\/10.1111\/j.1742-1241.2011.02728.x.","journal-title":"Int J Clin Pract"},{"key":"5250_CR18","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/bju.12006","volume":"112","author":"V Khullar","year":"2013","unstructured":"Khullar V, Cardozo L, Kelleher CJ, et al. Effects of drug cessation after flexible-dose fesoterodine in patients with overactive bladder. BJU Int. 2013;112:820\u20139. https:\/\/doi.org\/10.1111\/bju.12006 Epub 2013 Mar 7.","journal-title":"BJU Int"}],"container-title":["International Urogynecology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-022-05250-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00192-022-05250-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-022-05250-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T10:11:22Z","timestamp":1659348682000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00192-022-05250-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,6]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["5250"],"URL":"https:\/\/doi.org\/10.1007\/s00192-022-05250-1","relation":{},"ISSN":["0937-3462","1433-3023"],"issn-type":[{"value":"0937-3462","type":"print"},{"value":"1433-3023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,6]]},"assertion":[{"value":"16 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the local ethics committee (approval number: 28.08.2019:03).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}